Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore
1Both authors contributed equally to the work.
The tumor suppressor p53 is one of the most commonly mutated genes found in a wide range of cancers. Such mutations are associated with protein accumulation and increased presentation of p53-derived peptides on the surface of tumor cells as pMHCs that are recognized by specific CD8+ T cells. The p53 peptide 125–134 (p53125-134) was previously described as a wild-type sequence p53 derived peptide restricted by the MHC class I allele HLA-A*24:02, capable of activating peptide specific CD8+ cytotoxic T cells from peripheral blood mononuclear cells (PBMCs). Utilizing a TCR-like antibody that recognizes the p53125-134/HLA-A24 peptide MHC complex, we show that both in vitro and in vivo, p53125-134/HLA-A24 complexes can be detected on the surface of HLA-A24+ tumour cells that express mutant p53, thus validating the p53125-134/HLA-A24 as a physiologically relevant target for immunotherapy.
Credits: None available.
You must be logged in and own this product in order to